tree4cure.org

Sialidosis Info

Understanding Sialidosis, in plain language

A physician-reviewed overview of Type I and Type II Sialidosis — what causes it, what to watch for, and how it’s diagnosed. This page supports, but never replaces, guidance from your medical team.

The Basics

What causes Sialidosis?

Sialidosis is an ultra-rare, inherited lysosomal storage disorder. It’s caused by mutations in the NEU1 gene, which reduces or eliminates activity of the enzyme neuraminidase (sialidase) — leading to a build-up of sugar-linked molecules called sialylated compounds in cells throughout the body.

The Gene

NEU1, located on chromosome 6, provides instructions for making the enzyme neuraminidase 1.

The Enzyme

Neuraminidase normally breaks down sialic acid-containing molecules inside lysosomes, the cell’s recycling centers.

Inheritance

Sialidosis is autosomal recessive — a child must inherit a mutated copy of NEU1 from both parents.

Clinical Types

Type I vs. Type II at a glance

Presentation varies between individuals, even within the same type. This is general orientation, not a diagnostic tool.

Type I

Cherry-Red Spot Myoclonus Syndrome

Typically later-onset — late childhood through early adulthood

Progressive myoclonus (sudden, involuntary muscle jerks)
Cherry-red macular spot with gradually declining visual acuity
Seizures may develop as myoclonus progresses
Cognition is often preserved
Generally slower disease progression
Type II

Congenital, Infantile & Juvenile Forms

Typically earlier-onset — birth through early childhood

Cherry-red macular spot, often identified earlier
Coarser facial features and hepatosplenomegaly
Skeletal abnormalities (dysostosis multiplex)
Possible developmental / intellectual involvement
Faster progression, wider systemic involvement

Symptoms Overview

Signs that often prompt evaluation

No single symptom confirms Sialidosis — but this combination, especially together, should prompt specialist evaluation.

Myoclonus

Sudden, involuntary muscle jerks, often triggered by movement, touch, or startling.

Cherry-Red Spots

A distinctive red spot on the retina's macula, visible during a dilated eye exam.

Visual Decline

Gradually reduced visual acuity, sometimes progressing to significant vision loss over time.

Seizures

May develop as myoclonus becomes more frequent, particularly in Type I.

Hearing Changes

Sensorineural hearing loss has been reported, particularly in Type II forms.

Coarse Facial Features

More prominent in Type II — thickened facial features that may become apparent over time.

Organ Involvement

Hepatosplenomegaly (enlarged liver/spleen) is more common in Type II presentations.

Skeletal Changes

Dysostosis multiplex — a pattern of skeletal changes visible on imaging, mainly in Type II.

Getting Answers

The typical diagnostic pathway

Every case is different, and the order below can vary by clinician and geography — but this is the general path most families travel.

1

Clinical suspicion

A physician notices a pattern of symptoms — often myoclonus and vision changes — that doesn’t fit a more common diagnosis.

2

Dilated ophthalmologic exam

An eye specialist looks for the characteristic cherry-red macular spot, a strong diagnostic clue.

3

Enzyme activity assay

A blood or skin sample test measures neuraminidase (sialidase) activity levels.

4

NEU1 genetic testing

Sequencing confirms the specific NEU1 variant(s), clarifying type and informing family genetic counseling.

5

Confirmed diagnosis & care planning

A multidisciplinary care team is assembled — typically neurology, ophthalmology, genetics, and physical therapy.

Printable Physician Discussion Guide

A free 2-page PDF with focused questions to bring to appointments, plus a quick Type I vs. Type II reference table.

Scroll to Top